Jordan Alana Ciuro, MD, breaks down key factors to consider when determining whether to treat mHSPC with a doublet or triplet regimen, including disease burden, patient fitness, toxicity, and accessibility. Dr. Ciuro reviews findings from CHAARTED, STAMPEDE, TITAN, ENZAMET, ARASENS, and PEACE-1, highlighting when ADT with an ARSI is sufficient and when adding chemotherapy (docetaxel) may improve survival.
Doublet vs Triplet Therapy for mHSPC: Patient Selection and Treatment Considerations
By Jordan Ciuro, MD - Last Updated: February 28, 2025Related Posts
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.